Inotuzumab Ozogamicin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Inotuzumab Ozogamicin
- Inotuzumab ozogamicin: From B-Cell Acute Lymphoblastic Leukaemia to Drug-Induced Osteoporosis
Inotuzumab ozogamicin: From B-Cell Acute Lymphoblastic Leukaemia to Drug-Induced Osteoporosis
One-Sentence Summary
Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (calicheamicin payload), marketed in Singapore as Besponsa. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but 0 clinical trials and 0 publications specifically support this direction. The prediction rests on model output alone and has no plausible mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (from published literature; the Singapore licence record contains no indication text) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 98.24% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, inotuzumab ozogamicin is an anti-CD22 antibody linked to calicheamicin. After binding CD22 on B-cells, the complex is internalised and releases the payload, which causes double-strand DNA breaks and cell death.
The original indication is a B-cell malignancy that expresses CD22. Drug-induced osteoporosis is a bone-remodelling disorder with no connection to CD22-expressing cells. No mechanistic link could be identified.
The high score is most likely an artefact of the knowledge graph. The other top-10 predictions (several breast carcinoma subtypes, diabetic retinopathy, platelet and von Willebrand disorders, and a veterinary viral disease) are equally unsupported, which reinforces this conclusion. The drug's myelosuppression and thrombocytopenia would also argue against use in platelet-related conditions.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
Note: the literature retrieved by drug name for a lower-ranked prediction (luminal A/B breast tumour) concerned inotuzumab ozogamicin in B-cell acute lymphoblastic leukaemia, not breast cancer. These papers support the approved indication only. Examples include:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30920645 | 2019 | Phase 3 RCT | Cancer | Final INO-VATE results: inotuzumab ozogamicin vs standard-of-care chemotherapy in relapsed/refractory B-ALL, with long-term survival follow-up |
| 41026957 | 2025 | Clinical trial | J Clin Oncol | Inotuzumab followed by blinatumomab in older adults with newly diagnosed B-ALL (chemotherapy-free regimen) |
| 37187201 | 2023 | Phase 2 | Lancet Haematol | Mini-hyper-CVD plus inotuzumab, with or without blinatumomab, in older patients with Ph-negative B-ALL |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15747P | BESPONSA Powder for Concentrate for Solution for Infusion 1 mg/vial | Powder, for solution | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate with a cytotoxic calicheamicin payload (targeted cytotoxic therapy) |
| Myelosuppression Risk | High (myelosuppression and thrombocytopenia are expected with this class) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC (with differential and platelets), liver function (hepatotoxicity, including veno-occlusive disease, is a recognised risk) |
| Handling Protection | Handle according to cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs in total; 20 are listed in the data compiled for this report. Most are Moderate and a few are Major:
- Major: dolasetron, cisapride
- Moderate (examples): famotidine, loperamide, clarithromycin, levofloxacin, granisetron, palonosetron, bisacodyl, lactulose, polyethylene glycol, magnesium citrate and magnesium hydroxide
- Minor: metronidazole
Several of these (for example dolasetron, cisapride, clarithromycin, levofloxacin and the 5-HT3 antagonists) are commonly associated with QT prolongation, so the interaction list should be reviewed against the full label.
For warnings and contraindications, please refer to the package insert, as the data compiled for this report did not include label text.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only (L5), with no clinical trials or literature, and no biological link between a CD22-targeted cytotoxic conjugate and bone remodelling. The drug's toxicity profile (myelosuppression, hepatotoxicity) also makes repurposing for a non-malignant condition unattractive.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA record (currently missing, and a blocking gap for safety screening)
- Mechanism of action data confirmed from a primary source
- Any mechanistic or preclinical evidence linking CD22 biology or calicheamicin to bone metabolism (none identified so far)
- Review of other predictions, as none of the top 10 has supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.